Oncology News and Research RSS Feed - Oncology News and Research Twitter

Oncology, meaning bulk, mass, or tumor, and the suffix ''-logy'', meaning "study of") is a branch of medicine that deals with tumors (cancer). A medical professional who practices oncology is an ''oncologist''.
Study addresses the challenge of genomic heterogeneity

Study addresses the challenge of genomic heterogeneity

Known cancer-driving genomic aberrations in localized lung cancer appear to be so consistently present across tumors that a single biopsy of one region of the tumor is likely to identify most of them, according to a paper published today in Science. [More]
InSightec to share new insights at FUS symposium

InSightec to share new insights at FUS symposium

InSightec, world leader in MR-guided Focused Ultrasound (MRgFUS) will be on site at the Focused Ultrasound International Symposium (FUS) to share key insights gained in the past two years of using its non-invasive MRgFUS solution for treating a variety of neurosurgical, oncological and gynecological indications. [More]
CTCs in blood of metastatic cancer patients give genomic read-out of breast cancer

CTCs in blood of metastatic cancer patients give genomic read-out of breast cancer

The genetic fingerprint of a metastatic cancer is constantly changing, which means that the therapy that may have stopped a patient's cancer growth today, won't necessarily work tomorrow. [More]
GE Healthcare-Glaxo Smith Kline deal to create force in cancer testing

GE Healthcare-Glaxo Smith Kline deal to create force in cancer testing

A recently announced deal between GE Healthcare-subsidiary Clarient and Glaxo Smith Kline will create a force in cancer testing, according to Kalorama Information. The healthcare market research publisher tracks companion products, and says that the two entities will form a multi-purpose, data analytics- and companion diagnostics-driven network of laboratories. Kalorama Information recently released a market study, Companion Diagnostics Market, for companion diagnostics such as the drug-test combinations envisioned in this deal. [More]
VAL-083 drug compound shows promise against non-small cell lung cancer

VAL-083 drug compound shows promise against non-small cell lung cancer

DelMar Pharmaceuticals, Inc., a clinical-stage oncology company, today announced the presentation of promising new data supporting the activity of its lead drug compound, VAL-083, in the treatment of non-small cell lung cancer (NSCLC) at the AACR's New Horizons in Cancer Research: Harnessing Breakthroughs – Targeting Cures. The conference takes place October 9th to 12th in Pudong, Shanghai. [More]
CytRx begins Phase 1b trial of aldoxorubicin plus gemcitabine in patients with metastatic solid tumors

CytRx begins Phase 1b trial of aldoxorubicin plus gemcitabine in patients with metastatic solid tumors

CytRx Corporation, a biopharmaceutical research and development company specializing in oncology, today announced the initiation of enrollment in an open-label Phase 1b clinical trial designed to investigate the preliminary safety and activity of aldoxorubicin plus gemcitabine in subjects with metastatic solid tumors. [More]
Conventional laparoscopy less complicated than robot-assisted surgery for benign gynecologic conditions

Conventional laparoscopy less complicated than robot-assisted surgery for benign gynecologic conditions

For benign gynecologic conditions, robot-assisted surgery involves more complications during surgery and may be significantly more expensive than conventional laparoscopic surgery, according to a study by researchers at Columbia University Medical Center. [More]
Cancer Network presents exclusive coverage of ESMO 2014 Congress

Cancer Network presents exclusive coverage of ESMO 2014 Congress

UBM Medica US announces that Cancer Network, a leading online community for oncologists and others who treat cancer and the online home of the journal ONCOLOGY, presents exclusive coverage of the European Society for Medical Oncology (ESMO) 2014 Congress, held September 26–30 in Madrid, Spain. [More]
GenomOncology, med fusion partner to optimize treatment strategies for tumor

GenomOncology, med fusion partner to optimize treatment strategies for tumor

med fusion, an integrated molecular center of excellence and clinical trials service organization and GenomOncology, an Ohio based genomics technology and services provider, today announced a partnership to optimize treatment strategies based on the patient's disease state and tumor profile. [More]
C3BS inks preferred access agreement with Mayo Clinic

C3BS inks preferred access agreement with Mayo Clinic

Cardio3 BioSciences, a leader in the discovery, development and commercialization of regenerative, protective and reconstructive therapies, announces today the signing of a preferred access agreement with Mayo Clinic. [More]
Wolters Kluwer Health wins 12 prizes at 2014 BMA Medical Book Awards

Wolters Kluwer Health wins 12 prizes at 2014 BMA Medical Book Awards

Wolters Kluwer Health, a leading global provider of information solutions for the healthcare provider and education markets, today announced that its Lippincott Williams & Wilkins textbooks and digital guides were honored with 12 prizes at the 2014 BMA Medical Book Awards. [More]

UCSD researchers define epidemiology of gastrointestinal stromal tumors

Researchers at the University of California, San Diego School of Medicine have, for the first time, clearly defined the epidemiology of gastrointestinal stromal tumors (GIST), which occur primarily in the lining of the stomach and small intestine. [More]
Cyclophosphamide drug can eliminate life-threatening immune response after bone marrow transplants

Cyclophosphamide drug can eliminate life-threatening immune response after bone marrow transplants

Johns Hopkins and other cancer researchers report that a very short course of a chemotherapy drug, called cyclophosphamide, not only can prevent a life-threatening immune response in some bone marrow transplant recipients, but also can eliminate such patients' need for the usual six months of immune suppression medicines commonly prescribed to prevent severe forms of this immune response. [More]
Avidity NanoMedicines closes $6M convertible note financing, expands investor syndicate

Avidity NanoMedicines closes $6M convertible note financing, expands investor syndicate

Avidity NanoMedicines today announced that it has expanded its investor syndicate through the closing of a $6 million convertible note financing co-led by Fidelity Biosciences and TPG Biotech. [More]
Pinnacle initiates pivotal Phase 3 trial in Germany for rare form of bile duct cancer

Pinnacle initiates pivotal Phase 3 trial in Germany for rare form of bile duct cancer

Pinnacle Biologics, Inc., a subsidiary of Concordia Healthcare Corp., announced today the initiation of the pivotal Phase 3 trial (OPUS) in Germany for a rare form of bile duct cancer for which there is currently no acceptable therapy. [More]
CleveXel Pharma receives license for two new oncology patents

CleveXel Pharma receives license for two new oncology patents

CleveXel Pharma, a highly experienced pharmaceutical developer that conforms fully with global regulatory compliance, today announces that it has been granted a license by the SATT Sud Est, a technology transfer accelerator in South Eastern France (Societe d’Acceleration du Transfert de Technologies Sud Est), to exploit two patents. [More]
Penn Medicine to explore therapeutic strategies for HIV positive women at risk of cervical cancer

Penn Medicine to explore therapeutic strategies for HIV positive women at risk of cervical cancer

The introduction of antiretroviral drugs in Botswana over the last two decades has increased the life expectancies of people living with HIV—many of whom are women co-infected with the human papillomavirus virus (HPV)—considerably: from 39 years to the low 60s. As a result, this co-infected group of women is at a much higher risk of developing HPV-associated cervical cancer. [More]
UNM Cancer Center surgeon receives NCI's Cancer Clinical Investigator Team Leadership Award

UNM Cancer Center surgeon receives NCI's Cancer Clinical Investigator Team Leadership Award

Surgeon Teresa Rutledge, MD, recently received the National Cancer Institute's Cancer Clinical Investigator Team Leadership Award. Only 11 people nationwide received the award this year. Dr. Rutledge is the third faculty member in the history of the University of New Mexico Cancer Center to be recognized with this honor. [More]
New study finds geographic variation in use of laparoscopic colectomy for colon cancer patients

New study finds geographic variation in use of laparoscopic colectomy for colon cancer patients

Where patients live in the country may determine whether they receive minimally invasive colon cancer surgery. [More]
NanoString, BWH partner to translate genomic biomarker discoveries into clinical cancer diagnostics

NanoString, BWH partner to translate genomic biomarker discoveries into clinical cancer diagnostics

NanoString Technologies, Inc., a provider of life science tools for translational research and molecular diagnostic products, today announced that it has signed a multi-year, multi-investigator research collaboration with Harvard-affiliated Brigham and Women's Hospital to accelerate the translation of genomic biomarker discoveries into clinical cancer diagnostics. [More]